These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 15020613

  • 1. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE.
    J Clin Oncol; 2004 Mar 15; 22(6):1110-7. PubMed ID: 15020613
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 Mar 15; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC.
    J Clin Oncol; 2005 May 20; 23(15):3404-11. PubMed ID: 15824414
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M, Soda H, Soejima Y, Fukuda M, Kinoshita A, Takatani H, Kasai T, Nagashima S, Kawabata S, Doi S, Kohno S, Oka M.
    Cancer Chemother Pharmacol; 2006 Nov 20; 58(5):601-6. PubMed ID: 16463061
    [Abstract] [Full Text] [Related]

  • 9. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N, Takada M, Negoro S, Ota K, Fujita J, Furuse K, Ariyoshi Y, Ikegami H, Fukuoka M.
    Cancer; 1996 Jan 01; 77(1):63-70. PubMed ID: 8630941
    [Abstract] [Full Text] [Related]

  • 10. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D, Boddy A, Thomas H, Lind M, Newell D, Calvert AH, Robson L, Brampton M, Abrahamsen D, Winograd B.
    Semin Oncol; 1996 Dec 01; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
    Zarogoulidis K, Mylonaki E, Kakavelas P, Zarogoulidis P, Tsiouda T, Rapti E, Lithoxopoulou H, Zarogoulidou V, Kontakiotis T, Hellenic Pulmonary Oncology Study Group (HE.P.O.G.).
    Lung Cancer; 2009 Nov 01; 66(2):226-30. PubMed ID: 19321222
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
    You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G.
    Lung Cancer; 2008 Nov 01; 62(2):261-72. PubMed ID: 18442869
    [Abstract] [Full Text] [Related]

  • 17. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer.
    Evans WK, Radwi A, Tomiak E, Logan DM, Martins H, Stewart DJ, Goss G, Maroun JA, Dahrouge S.
    Am J Clin Oncol; 1995 Apr 01; 18(2):149-55. PubMed ID: 7534977
    [Abstract] [Full Text] [Related]

  • 18. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    Lung Cancer; 2006 Jul 01; 53(1):67-75. PubMed ID: 16713013
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, Spigel DR, Joseph G, Corso SW, Spremulli E, Hainsworth JD.
    Oncologist; 2005 Oct 01; 10(9):728-33. PubMed ID: 16249353
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
    Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG.
    J Clin Oncol; 2005 Jun 20; 23(18):4089-99. PubMed ID: 15867202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.